论文部分内容阅读
目的 观察12 5I 抗AFP抗体经肝动脉灌注后在癌灶内的定位导向能力及与化疗栓塞(TACE)联合治疗肝癌的近期疗效和毒副作用。方法 肝动脉内介入灌注12 5I 抗AFP抗体联合行TACE ,综合治疗肝癌 36例。结果 导向组瘤 肝放射比值平均为 1 86± 0 72 ,有效率、AFP显著下降率及中位缓解期与TACE组相比 ,各为 55 6 %比 4 1 2 % (P >0 0 5)、77 8%比 52 9% (P <0 0 5)、8 5M比 5 6M(P <0 0 5)。两组的毒性反应相似。结论 经肝动脉灌注并与TACE联合可显著增强12 5I 抗AFP抗体在肝癌灶中的导向定位能力和滞留能力及内照射作用 ,提高综合疗效。
Objective To observe the localization-oriented ability of 12 5I anti-AFP antibody after hepatic artery perfusion in cancer foci and the short-term curative effect and side effects of combined chemotherapy and embolization (TACE) for liver cancer. Methods Intrahepatic arterial infusion of 12 5I anti-AFP antibody was combined with TACE to treat 36 cases of liver cancer. Results The ratio of tumor to liver radiotherapy in the guide group was 186±0.72. The effective rate, AFP decrease rate, and median remission period were 55.6 % and 41.2% respectively compared with the TACE group (P > 0 05). , 77 8% than 52 9% (P <0 0 5), 8 5M than 5 6M (P <0 0 5). The toxicity of the two groups is similar. Conclusions Infusion of hepatic artery combined with TACE can significantly enhance the localization and retention of 125I anti-AFP antibodies in hepatoma tumors, as well as the internal irradiation effect, and improve the overall efficacy.